MannKind Corporation (NASDAQ:MNKD) Stock Has Average Target Price of $8.08

Posted by Geri Gentry on Nov 13th, 2026

Shares of MannKind Corporation (NASDAQ:MNKD – Get Free Report) have earned an average recommendation of “Moderate Buy” from the ten research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $8.50.

A number of equities research analysts have recently issued reports on the stock. Royal Bank Of Canada upped their price objective on shares of MannKind from $4.75 to $5.00 and gave the company a “sector perform” rating in a research note on Friday, November 6th. HC Wainwright reaffirmed a “buy” rating on shares of MannKind in a report on Thursday, July 23rd. Wells Fargo & Company decreased their target price on shares of MannKind from $14.00 to $13.00 and set an “overweight” rating on the stock in a research report on Thursday, August 6th. Wall Street Zen raised shares of MannKind from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Finally, Zacks Research raised shares of MannKind from a “strong sell” rating to a “hold” rating in a research note on Monday, October 5th.

Check Out Our Latest Analysis on MannKind

Insiders Place Their Bets

In other MannKind news, Director Steven Binder sold 39,051 shares of the business’s stock in a transaction that occurred on Friday, September 25th. The stock was sold at an average price of $3.29, for a total value of $128,477.79. Following the completion of the sale, the director owned 713,258 shares in the company, valued at approximately $2,346,618.82. The trade was a 5.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. First Trust Advisors LP purchased a new position in shares of MannKind in the third quarter worth $7,301,000. Private Advisor Group LLC purchased a new stake in shares of MannKind during the third quarter worth about $65,000. Voya Investment Management LLC boosted its holdings in shares of MannKind by 246.4% during the third quarter. Voya Investment Management LLC now owns 737,655 shares of the biopharmaceutical company’s stock worth $2,877,000 after purchasing an additional 524,726 shares during the period. Global Retirement Partners LLC grew its stake in shares of MannKind by 245.4% in the third quarter. Global Retirement Partners LLC now owns 8,636 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 6,136 shares during the last quarter. Finally, Alps Advisors Inc. grew its stake in shares of MannKind by 36.4% in the third quarter. Alps Advisors Inc. now owns 426,020 shares of the biopharmaceutical company’s stock worth $1,661,000 after purchasing an additional 113,669 shares during the last quarter. Institutional investors own 49.55% of the company’s stock.

MannKind Price Performance

NASDAQ:MNKD opened at $4.16 on Friday. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of -18.09 and a beta of 1.10. The business has a 50 day moving average of $3.57 and a 200 day moving average of $3.69. MannKind has a 1-year low of $2.23 and a 1-year high of $6.51.

MannKind (NASDAQ:MNKD – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.06. The business had revenue of $101.87 million for the quarter, compared to the consensus estimate of $107.74 million. The firm’s revenue was up 24.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.03 earnings per share. As a group, sell-side analysts anticipate that MannKind will post -0.20 EPS for the current year.

MannKind Company Profile

(Get Free Report)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).